🟢 Context Therapeutics is trading 6.11% up today despite a weaker broader market

Context Therapeutics is trading 6.11% up at $0.37 on September 14, 2026, with no clear company-specific catalyst or major announcement identified.

• The latest company release was September 9, when Context Therapeutics announced the first patient dosed in its Phase 1 CT-202 trial, several days before the current move.
• Major indices are declining, so the gain cannot confidently be attributed to broad market sentiment.
• The movement appears speculative or technically driven, with limited confirmed news support.